



Clearside Biomedical Announces Multiple Presentations on its Suprachoroidal Space® Injection Platform at Upcoming Medical Meetings

April 18, 2019

Posters to be presented on gene therapy and visual acuity

ALPHARETTA, Ga., April 18, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple presentations will be made on Clearside's Suprachoroidal Space (SCS[®]) injection platform at upcoming ophthalmology and gene therapy medical meetings in Vancouver, British Columbia. The presentations will highlight the benefits of the Company's SCS injection platform when utilized in uveitis patients and with gene therapy.

Viral Kansara, Ph.D., Clearside Vice President, Discovery, will give an oral presentation at the 6th Annual Retinal Cell and Gene Therapy Innovation Summit

Title: Suprachoroidally delivered non-viral DNA nanoparticles transfect chorioretinal cells in non-human primates and rabbits
Date: Friday, April 26, 2019
Time: 5:30 pm – 5:45 pm

Eric B. Suhler M.D., M.P.H., Oregon Health and Science University Professor of Ophthalmology and Co-Director, OHSU Uveitis Clinic, will give an oral presentation at the American Uveitis Society Spring Meeting 2019

Title: Suprachoroidal Administration of Triamcinolone Acetonide (CLS-TA) For the Treatment of Macular Edema in Noninfectious Uveitis: Pooled Results of Three Clinical Trials
Date: Saturday, April 27, 2019
Event Time: 5:00 pm – 7:30 pm

Three poster presentations will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Conference taking place April 28 – May 2, 2019

Title: Suprachoroidal injection of AAV8 for ocular gene delivery in the nonhuman primate
Date: Tuesday, April 30, 2019
Time: 8:45 am – 10:30 am
Session: Gene Therapy and Delivery
Poster #: A0091
Abstract #: 2904 - A0091

Title: Suprachoroidally delivered non-viral DNA nanoparticles transfect chorioretinal cells in non-human primates and rabbits
Date: Tuesday, April 30, 2019
Time: 8:45 am – 10:30 am
Session: Gene Therapy and Delivery
Poster #: A0096
Abstract #: 2909 - A0096

Title: Treatment response analysis of visual acuity and central subfield retinal thickness following suprachoroidal CLS-TA
Date: Tuesday, April 30, 2019
Time: 11:45 am – 1:30 pm
Session: Uveitis and scleritis - clinical therapeutics and checkpoint inhibitors
Poster #: A0552
Abstract #: 3511 - A0552

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases. Clearside's proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The company's unique platform for eye disease treatments is inherently flexible and intended to work with established medicines, new formulations of medicines, as well as future innovations such as gene therapy. Clearside is headquartered in Alpharetta, GA. For more information, please visit <http://www.clearsidebio.com>.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in

the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential benefits of SCS Injection Platform. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 15, 2019, and Clearside’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.



Source: Clearside Biomedical, Inc.